Biomatrix (BXM) Looking Great Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biomatrix (BXM) Looking Great

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John McCarthy who wrote (87)	9/11/1997 1:34:00 AM
From: Eduardo Canto	of 569

John, a) The anti-adhesion market is a billion $ market. The costs of complications due to post-op adhesions is about $2 billion. There are rgreater than 3 million surgeries annually in which anti-adhesion products may be used. For example, there are 1.8 million open abdominal and 1.3 million open pelvic procedures which carry risks of postoperative adhesion-related complications. b) I don't think that you can get expedited review of an anti-adhesion product since adheisons are generally not life threatening even though the morbidity is high. c) I would expect one to be able to run ph I-III trials in a couple of years since most studies look at development of adhesion within weeks to months after surgery. d) Current players include: Genzyme (with their various "sepra" products such as Seprafilm), Lifecore (Lubricoat with J&J), Anika (Insert product), Focal, Gliatech, Osteotech and W.L. Gore. e) I agree, nothing out there is a showstopper, yet! Best of luck, E.C.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next